title: Letter to the Editor: Comment on "SGLT2 inhibitors may predispose to ketoacidosis" by Taylor S.I., et al.
authors: Center for Pharmacy and Experimental Therapeutics, University of Georgia College of Pharmacy, Augusta, Georgia 30912; Charlie Norwood Veterans Affairs Medical Center, August, Georgia 30912; Vascular Biology Center, Department of Pharmacology and Toxicology, Georgia Regents University, Augusta, Georgia 30912; and Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033.
authors: Lakshman
authors: L
authors: Segar
mesh_terms: D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors